CO2023014204A2 - Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) - Google Patents

Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)

Info

Publication number
CO2023014204A2
CO2023014204A2 CONC2023/0014204A CO2023014204A CO2023014204A2 CO 2023014204 A2 CO2023014204 A2 CO 2023014204A2 CO 2023014204 A CO2023014204 A CO 2023014204A CO 2023014204 A2 CO2023014204 A2 CO 2023014204A2
Authority
CO
Colombia
Prior art keywords
nek7
inhibitors
never
compounds
related kinase
Prior art date
Application number
CONC2023/0014204A
Other languages
English (en)
Spanish (es)
Inventor
John Sai Keong Kauwe Iii
Alexis Henri Abel Mollard
David James Bearss
Original Assignee
Halia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halia Therapeutics Inc filed Critical Halia Therapeutics Inc
Publication of CO2023014204A2 publication Critical patent/CO2023014204A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CONC2023/0014204A 2021-04-05 2023-10-24 Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) CO2023014204A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170708P 2021-04-05 2021-04-05
US202163185282P 2021-05-06 2021-05-06
PCT/US2022/023443 WO2022216680A1 (en) 2021-04-05 2022-04-05 Nek7 inhibitors

Publications (1)

Publication Number Publication Date
CO2023014204A2 true CO2023014204A2 (es) 2023-11-10

Family

ID=81448482

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0014204A CO2023014204A2 (es) 2021-04-05 2023-10-24 Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)

Country Status (11)

Country Link
EP (1) EP4320127A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024513227A (cg-RX-API-DMAC7.html)
KR (1) KR20230175222A (cg-RX-API-DMAC7.html)
AU (1) AU2022255486A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023019435A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214042A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023014204A2 (cg-RX-API-DMAC7.html)
IL (1) IL307258A (cg-RX-API-DMAC7.html)
MX (1) MX2023011464A (cg-RX-API-DMAC7.html)
PH (1) PH12023552774A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022216680A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
WO2024059200A1 (en) * 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors
EP4671246A1 (en) * 2023-02-24 2025-12-31 Japan Tobacco Inc. COMPOSITE OF 6-ALCOXYPYRAZOLOPYRIMIDINE AND ITS PHARMACEUTICAL USE
TW202448887A (zh) * 2023-02-24 2024-12-16 日商日本煙草產業股份有限公司 取代吡唑并嘧啶化合物及其醫藥用途
AU2024240240A1 (en) * 2023-03-17 2025-09-25 Ventus Therapeutics U.S., Inc. Urea derivatives for inhibiting nlrp3 and uses thereof
WO2025067411A1 (zh) * 2023-09-28 2025-04-03 北京普祺医药科技股份有限公司 一种nek7抑制剂、药物组合物及其用途
CN122535593A (zh) * 2023-12-29 2026-08-07 北京普祺医药科技股份有限公司 一种nek7抑制剂、药物组合物及其用途
WO2026064385A1 (en) * 2024-09-18 2026-03-26 Ventus Therapeutics U.S., Inc. Oxadiazolone inhibitors of nlrp3 and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
ATE446962T1 (de) 2004-12-17 2009-11-15 Lilly Co Eli Thiazolopyridinon-derivate als mch- rezeptorantagonisten
CN101558068A (zh) 2006-10-16 2009-10-14 诺瓦提斯公司 用作蛋白激酶抑制剂的苯乙酰胺类
JP2010531887A (ja) 2007-06-26 2010-09-30 グラクソスミスクライン エルエルシー ベンズイミダゾールチオフェンの調製方法
US8980899B2 (en) * 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
US9321763B2 (en) 2012-04-04 2016-04-26 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
CN103421005A (zh) 2012-05-16 2013-12-04 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
EP2917214B1 (en) 2012-11-07 2019-08-28 Nerviano Medical Sciences S.r.l. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
CN105431436B (zh) 2013-05-14 2017-11-28 内尔维阿诺医学科学有限公司 吡咯并[2,3‑d]嘧啶衍生物,它们的制备方法和它们作为激酶抑制剂的用途
WO2014206343A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
EP3102195B1 (en) 2014-02-03 2021-10-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
WO2016029776A1 (en) 2014-08-26 2016-03-03 Astar Biotech Llc Protein kinase inhibitors
CN105837575B (zh) 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
MX376201B (es) 2015-12-30 2025-03-07 Nqp 1598 Ltd Compuestos inhibidores de metaloenzima.
CN107513068A (zh) 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
ES2921257T3 (es) 2016-06-20 2022-08-22 Daegu Gyeongbuk Medical Innovation Found Nuevo derivado de imidazopiridina, procedimiento para prepararlo y composición farmacéutica que contiene el mismo como ingrediente activo para prevenir o tratar el cáncer
KR102500416B1 (ko) 2016-06-21 2023-02-17 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서의 n-(치환된-페닐)-설폰아미드 유도체
EP3296297A1 (en) 2016-09-15 2018-03-21 Centre National De La Recherche Scientifique Benzimidazol derivatives for treating filovirus infection
WO2018102751A1 (en) 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
WO2018215668A1 (en) 2017-05-26 2018-11-29 Glenmark Pharmaceuticals S.A. Novel inhibitors of map4k1
WO2018222917A1 (en) 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
EP3774797B1 (en) * 2018-04-05 2025-11-19 Merck Patent GmbH Heteroaryl compounds as type ii irak inhibitors and uses hereof
EP3778590A4 (en) 2018-04-09 2021-12-22 ShanghaiTech University ANTI PROTEIN DEGRADATION COMPOUND, ANTITUMOR APPLICATION, INTERMEDIATE THEREOF, AND INTERMEDIATE USE
WO2019200120A1 (en) 2018-04-11 2019-10-17 Lycera Corporation Dihydroisoquinoline-2(1h)-carboxamide and related compounds and their use in treating medical conditions
TWI848954B (zh) 2018-06-13 2024-07-21 英屬開曼群島商百濟神州有限公司 作為hpk1抑制劑的吡咯並[2,3-b]吡啶或吡咯並[2,3-b]吡嗪及其用途
CN111377907B (zh) 2018-12-26 2023-03-28 杭州百新生物医药科技有限公司 一种多取代苯氨基嘧啶衍生物及其制备方法和用途
CN111646995B (zh) * 2019-03-04 2023-03-21 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
WO2020206583A1 (en) 2019-04-08 2020-10-15 Qilu Regor Therapeutics Inc. Kinase inhibitors and uses thereof
KR20220066290A (ko) * 2019-08-29 2022-05-24 히버셀, 인크. Perk 억제 피롤로피리미딘 화합물
CN112552302B (zh) * 2019-09-26 2022-05-13 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
CN114761000A (zh) 2019-10-01 2022-07-15 金翅雀生物公司 Cdk5的取代的1,6-萘啶抑制剂
JP7461605B2 (ja) 2020-02-20 2024-04-04 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 キノリン系化合物
US20230210853A1 (en) 2020-05-08 2023-07-06 Halia Therapeutics, Inc. Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
CN113717156B (zh) 2020-05-25 2023-05-09 南京红云生物科技有限公司 Egfr抑制剂、其制备方法及用途
GB202010464D0 (en) 2020-07-08 2020-08-19 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Also Published As

Publication number Publication date
EP4320127A1 (en) 2024-02-14
KR20230175222A (ko) 2023-12-29
JP2024513227A (ja) 2024-03-22
IL307258A (en) 2023-11-01
WO2022216680A1 (en) 2022-10-13
US20240317758A1 (en) 2024-09-26
CA3214042A1 (en) 2022-10-13
BR112023019435A2 (pt) 2023-10-24
PH12023552774A1 (en) 2024-04-15
AU2022255486A1 (en) 2023-10-19
MX2023011464A (es) 2023-10-19

Similar Documents

Publication Publication Date Title
CO2022017622A2 (es) Inhibidores de quinasa nek7
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CO2022019131A2 (es) Inhibidores de la quinasa nek7
MX2021008358A (es) Lipidos para la administracion de agentes activos en nanoparticulas lipidicas.
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
CL2024001466A1 (es) Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos
PY1996328A (es) Compuestos de azalactam como inhibidores de hpk1
CO2024015820A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
MX388781B (es) Compuestos de quinazolina sustituido y su uso como inhibidores de proteínas kras, hras y/o nras mutantes g12c.
PH12023552774A1 (en) Nek7 inhibitors
CO2024015816A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2022005732A (es) Derivado de amida y metodo de preparacion para el mismo y uso del mismo en medicina.
MX2025007218A (es) Moduladores del inflamasoma nlrp3 y productos y metodos relacionados
MX2024010321A (es) Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
CO2026000093A2 (es) Composiciones farmacéuticas para inhibidores de la cinasa nek7
MX2021009194A (es) Composiciones insecticidas resistentes a la degradación del ingrediente activo y proceso para la preparación de estas.
MX2023012958A (es) Compuestos y metodos anticonceptivos.
CO2023012903A2 (es) Derivados de pirimidina útiles como inhibidores de la proteína cinasa de repetición 2 rica en leucina (lrrk2)
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
AR124698A1 (es) Derivados tricíclicos útiles como inhibidores de parp7
AR130252A1 (es) Inhibidores enzimáticos
AR131249A1 (es) Derivados de heteroarilo bicíclicos útiles como agentes anticancerígenos
DOP2025000073A (es) Combinación de compuestos de 2,4 diamino-quinolina sustituida e inhibidores de la proteína quinasa quinasa activada por mitógeno (mek) para ser utilizada en el tratamiento de cánceres hepáticos